IP Library Granted Patent US 11,638,723
Granted Patent B2
US 11,638,723 · App. 17/173,632 · Granted May 2, 2023

Method for generating T cells progenitors

Inventors: Isabelle André (Issy les Moulineaux, FR); Marina Cavazzana (Paris, FR); Kuiying Ma (Paris, FR); John Tchen (Pantin, FR); Tayebeh-Shabi Soheili (Paris, FR); Ranjita Devi Moirangthem (Paris, FR)
Assignees: Assistance Publique—Hopitaux de Paris; Fondation Imagine—Institut des Maladies Génétiques; Université Paris Cité; Institut National de la Santé et de la Recherche Médicale (INSERM)
A61K35/17C12N5/0636C12N2501/125C12N2501/145C12N2501/2307C12N2501/25C12N2501/26C12N2501/42C12N2506/11C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,638,723
App. No.
17/173,632
Granted
May 2, 2023
Kind
B2
Abstract

The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Claims (10)

1. An isolated T cell progenitor population comprising CD7+ T cell progenitors,

wherein said CD7+ T cell progenitors comprise CD34−CD7+ T cell progenitors, wherein more than 80% of the CD7+ T cell progenitors are CD34−CD7+ T cell progenitors,

wherein said CD34−CD7+ T cell progenitors comprise T cell progenitors with the following phenotype: CD7+CD34−CD1a−CD5−,

wherein said T cell progenitor population was prepared by culturing CD34+ cells in a culture medium comprising fetal serum, TNF-alpha, IL-7, thrombopoietin (TPO), Flt3L, and Stem cell factor (SCF), in the presence of an immobilized Delta-like-4 ligand and a fibronectin fragment for a period ranging from 5 to 7 days, wherein said fibronectin fragment comprises the RGDS (SEQ ID NO: 3) and connecting segment 1 (CS-1) patterns as well as a heparin-binding domain, wherein TNF-alpha is present in the culture medium at a concentration of at least 10 ng/m L,

wherein fetal serum is present in the culture medium at a concentration of at least 15%, and

wherein the culture medium does not comprise IL 3.

2. The isolated T cell progenitor population according to claim 1 , wherein the CD7+CD34− cells are genetically modified by the introduction of a vector, wherein the vector encodes a Chimeric Antigen Receptor (CAR).

3. The isolated T cell progenitor population of claim 1 , wherein the CD34+ cells are isolated from a human.

4. The isolated T cell progenitor population of claim 1 , wherein the CD34+ cells are isolated from an adult donor.

5. The isolated T cell progenitor population of claim 1 , wherein more than 80% of the CD7+ T cell progenitors are CD7+CD34−CD5−, CD7+CD34−CD1a−, or CD7+CD34−CD1a−CD5−.

Assignments (4)
MERGER Recorded Aug 3, 2022
From: UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 060709/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2022
From: ANDRÉ, ISABELLE; CAVAZZANA, MARINA; MA, KUIYING; TCHEN, JOHN
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES; UNIVERSITÉ PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
Reel/Frame 060696/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2022
From: SOHEILI, TAYEBEH-SHABI; DEVI MOIRANGTHEM, RANJITA
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; FONDATION IMAGINE - INSTITUT DES MALADIES GÉNÉTIQUES; UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 060502/0144 →
CHANGE OF NAME Recorded Jun 17, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060530/0623 →
Priority Claims (1)
EP 17305161 · Feb 13, 2017 · regional
Continuity (3)
Division 17010208 · Sep 2, 2020
Continuation 16485488
Related Publication 20210169934A1 · Jun 10, 2021